Driven by an increase in sales in the United States, India's biggest drug manufacturer Ranbaxy recorded a more than two fold jump in its net profit, which stood at 312.8 crore for the three month period ended September 30.

Ranbaxy, which made a net profit of 116.6 crore during July-Sep 2009, also gained from constructive Forex movement duirng the third quarter.

Ranbaxy managing director Arun Sawhney stated, "Our key markets continued to perform well attributable in large measure to balanced sales across geographies. This has also been aided by favourable Forex movement."

The key markets of the company all over the world comprise North America, India, Romania, CIS and Latin America.

The total operating income of the Gurgaon-based company grew to 1,934.6 crore for the third quarter as compared to Rs 1,885.8 crore in the same period of 2009.

During the three month period ended September 2010, the company's sales increased 70% to 491.2 crore in North American region.

Ranbaxy's domestic sales during the period under review remained at 493 crore for the third quarter, whereas CIS region`s sales stood at 120.9 crore.

The African sales of the company stood at 164.4 crore for the third quarter.

"As we move forward, our focus will be on bettering operational performance, maximising synergies with Daiichi Sankyo and on seeking a speedy resolution to the challenges in the USA," Mr. Sawhney added.